Teladoc Insider Adam Vandervoort Boosts Shares, Signals Confidence in Teladoc’s Turnaround

Insider Activity at Teladoc Health: A Close‑Read on Adam C. Vandervoort’s Recent Moves

Teladoc Health’s stock has experienced significant volatility this year, closing at $4.54 on 23 February 2026 after falling from a 2025 high of $10.02. Amid this turbulence, Chief Legal Officer Adam C. Vandervoort has increased his holdings through a series of conversions and purchases that shed light on how the company’s leadership is positioning itself for the next fiscal cycle.

Conversion‑Driven Accumulation

• 27 Feb 2026: Vandervoort converted 12,418 restricted‑stock units (RSUs) and 3,322 performance‑stock units (PSUs) into common shares, adding approximately 24,740 shares to his portfolio.
• The same day, he purchased 1,510 PSUs, bringing his total ownership to 130,322 shares.
• These conversions—both tied to performance milestones—indicate that Vandervoort expects Teladoc’s metrics to improve. The timing also coincides with a modest 0.12 % price increase to $5.10, a 180‑percent buzz spike on social media, and a sentiment score of +93, suggesting that the market is reacting positively to his moves.

Balancing Act: Selling to Cover Taxes

• Shortly after the conversions, Vandervoort sold 27,083 shares to cover the tax obligations tied to the vesting of the newly converted shares.
• The sale price of $5.12 per share is only marginally above the conversion price, implying that the transaction was driven primarily by tax logistics rather than a strategic divestiture.
• This pattern of conversion followed by a tax‑cover sale is common among insiders and indicates a disciplined approach to equity management.

Historical Patterns: A Gradual Accumulation

• Vandervoort’s past insider filings reveal a consistent trend of buying common stock, often in the range of 4,400 to 5,350 shares, interspersed with occasional RSU and PSU sales.
• Since mid‑2025, his holdings have risen steadily from 71,278 shares to 130,322, reflecting a net accumulation of roughly 59,000 shares over a year.
• The choice to convert RSUs and PSUs rather than sell them outright suggests confidence in Teladoc’s ability to hit its performance targets, especially as the company navigates a challenging earnings environment (P/E of –3.54).

Implications for Investors

Who is Adam C. Vandervoort?

• Beyond his role as Chief Legal Officer and Secretary, Vandervoort has been a steady presence on Teladoc’s board since 2024.
• His past transactions show a preference for long‑term, performance‑linked equity rather than short‑term speculation.
• His recent conversion activity underscores a strategic tilt toward aligning his interests with the company’s growth trajectory, a move that may resonate with value‑oriented investors seeking alignment between management and shareholder interests.

Bottom Line

Vandervoort’s recent insider activity—conversion of RSUs and PSUs followed by a tax‑cover sale—reflects a measured strategy aimed at cementing his stake while managing tax liabilities. For investors, the steady accumulation signals confidence in Teladoc’s prospects, even as the stock remains in a narrow trading range and earnings remain negative. Monitoring subsequent insider transactions, particularly from other senior leaders, will be key to assessing whether this confidence translates into a sustained turnaround for the telemedicine pioneer.

Key Transaction Table (Condensed)

All values are taken from SEC Form 4 filings filed on the specified dates.